As of the six months ended June 30, 2024, fosun pharma announced its interim performance, achieving revenue of RMB 20,383 million, a decrease of 4.38% year-on-year. The gross profit was RMB 9,920 million, with a slight decrease in gross margin. During the period, the company realized a profit attributable to the shareholders of the parent company of RMB 1,225 million, a decrease of 31.33% year-on-year. EBITDA was RMB 4,154 million, a decrease of 13.31% year-on-year. The company's operating cash flow was RMB 1,907 million, an increase of 5.36% year-on-year. During the reporting period, the company continued to promote lean management, optimize the asset structure, complete disposals, and signed pending disposals totaling more than RMB 2,000 million. In addition, the company's total R&D investment amounted to RMB 2,737 million, with R&D expenses of RMB 1,862 million. The company later announced the implementation of a merger and privatization plan for henlius after the reporting period.

As of the six months ended June 30, 2024, fosun pharma announced its interim performance, achieving revenue of RMB 20,383 million, a decrease of 4.38% year-on-year. The gross profit was RMB 9,920 million, with a slight decrease in gross margin. During the period, the company realized a profit attributable to the shareholders of the parent company of RMB 1,225 million, a decrease of 31.33% year-on-year. EBITDA was RMB 4,154 million, a decrease of 13.31% year-on-year. The company's operating cash flow was RMB 1,907 million, an increase of 5.36% year-on-year. During the reporting period, the company continued to promote lean management, optimize the asset structure, complete disposals, and signed pending disposals totaling more than RMB 2,000 million. In addition, the company's total R&D investment amounted to RMB 2,737 million, with R&D expenses of RMB 1,862 million. The company later announced the implementation of a merger and privatization plan for henlius after the reporting period.